TG Therapeutics Completes $100 Million Stock Repurchase and Approves New Repurchase Plan

Summary

TG Therapeutics, Inc. has completed a $100 million share buyback, repurchasing approximately 3.5 million shares at an average price of $28.55 each. The Board of Directors has also authorized a new $100 million share repurchase program, which will be executed based on market conditions and applicable laws.Reuters

Impact Analysis

So basically, TG Therapeutics is doubling down on its share buyback strategy, having just completed a $100 million repurchase and immediately authorizing another $100 million program. This move suggests management is confident in the company’s growth trajectory, particularly with its multiple sclerosis therapy, Briumvi, which CEO Michael S. Weiss highlighted as a key growth driver.Benzinga The timing is interesting—right after a successful buyback, they’re signaling continued optimism. The stock’s recent rise of 6.32% to $31.61, trading above its 200-day moving average, indicates a bullish sentiment.Benzinga Market’s missing that this isn’t just about returning capital; it’s a vote of confidence in future earnings potential. Watch for how this impacts investor sentiment and whether competitors feel pressured to follow suit. The risk is if growth doesn’t materialize as expected, but for now, the setup looks favorable.